Your browser doesn't support javascript.
Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
Saita, Mizue; Yan, Yan; Ito, Kanami; Sasano, Hiroshi; Seyama, Kuniaki; Naito, Toshio.
  • Saita M; Department of General Medicine, Juntendo University Faculty of Medicine, Japan; Department of Safety and Health Promotion, Juntendo University, Japan.
  • Yan Y; Department of Palliative Medicine, Juntendo University Graduate School of Medicine, Japan.
  • Ito K; Department of Safety and Health Promotion, Juntendo University, Japan.
  • Sasano H; Department of Pharmacy, Juntendo University Hospital, Japan.
  • Seyama K; Department of Safety and Health Promotion, Juntendo University, Japan; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Japan.
  • Naito T; Department of General Medicine, Juntendo University Faculty of Medicine, Japan; Department of Safety and Health Promotion, Juntendo University, Japan. Electronic address: naito@juntendo.ac.jp.
J Infect Chemother ; 28(1): 116-119, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1440193
ABSTRACT
As the first authorized COVID-19 vaccine in Japan, the BNT162b2 mRNA COVID-19 vaccine is utilized for mass vaccination. Although efficacy has been proved, real-world evidence on reactogenicity in Japanese personnel is needed to prepare the public. Healthcare workers in a large academic hospital in Japan received two doses of the Pfizer-BioNTech vaccine from March 17 to May 19, 2021. Online questionnaires were distributed to registered recipients following each dose, from day 0 through day 8. Primary outcomes are the frequency of reactogenicity including local and systemic reactions. Length of absence from work was also analyzed. Most recipients self-reported reactogenicity after the first dose (97.3%; n = 3254; mean age [36.4]) and after the second dose (97.2%; n = 3165; mean age [36.5]). Systemic reactions following the second dose were substantially higher than the first dose, especially for fever (OR, 27.38; 95% CI, [22.00-34.06]; p < 0.001), chills (OR, 16.49; 95% CI, [13.53-20.11]; p < 0.001), joint pain (OR, 8.49; 95% CI, [7.21-9.99]; p < 0.001), fatigue (OR, 7.18; 95% CI, [6.43-8.02]; p < 0.001) and headache (OR, 5.43; 95% CI, [4.80-6.14]; p < 0.001). Reactogenicity was more commonly seen in young, female groups. 19.3% of participants took days off from work after the second dose (2.2% after the first dose), with 4.7% absent for more than two days. Although most participants reported reactogenicity, severe cases were limited. This study provides real-world evidence for the general population and organizations to prepare for BNT162b2 mRNA COVID-19 vaccination in Japan and other countries in the region.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2021.09.009

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Topics: Vaccines Limits: Female / Humans Country/Region as subject: Asia Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2021.09.009